<html><body><h2>Case: 1015413</h2><h3> CDS Time: 2011-05-31</h3>
<patient name=1015413>
59.0 year old White_Non-Hispanic Male
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">59</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">Calcium</td><td width="200">9</td><td width="200">1959-9-19</td></tr>
<tr><td width="200">Alkaline_phosphatase</td><td width="200">88</td><td width="200">1959-9-19</td></tr>
<tr><td width="200">Phosphorus</td><td width="200">3</td><td width="200">1959-5-15</td></tr>
<tr><td width="200">LDL_Cholesterol</td><td width="200">87</td><td width="200">1959-9-19</td></tr>
<tr><td width="200">Chloride</td><td width="200">106.0</td><td width="200">1959-9-19</td></tr>
<tr><td width="200">HDL_Cholesterol</td><td width="200">52</td><td width="200">1959-9-19</td></tr>
<tr><td width="200">Diastolic_BP</td><td width="200">68</td><td width="200">1959-7-28</td></tr>
<tr><td width="200">Weight</td><td width="200">175</td><td width="200">1959-7-28</td></tr>
<tr><td width="200">HbA1C</td><td width="200">6</td><td width="200">1957-12-10</td></tr>
<tr><td width="200">Triglycerides</td><td width="200">146</td><td width="200">1959-9-19</td></tr>
<tr><td width="200">Total_Cholesterol</td><td width="200">165</td><td width="200">1959-9-19</td></tr>
<tr><td width="200">SGOT</td><td width="200">21</td><td width="200">1959-9-19</td></tr>
<tr><td width="200">Systolic_BP</td><td width="200">116</td><td width="200">1959-7-28</td></tr>
<tr><td width="200">Total_Bilirubin</td><td width="200">0</td><td width="200">1959-9-19</td></tr>
<tr><td width="200">Height</td><td width="200">64</td><td width="200">1959-7-28</td></tr>
<tr><td width="200">Potassium</td><td width="200">4</td><td width="200">1959-9-19</td></tr>
<tr><td width="200">Cholesterol</td><td width="200">165</td><td width="200">1959-9-19</td></tr>
<tr><td width="200">BUN</td><td width="200">18</td><td width="200">1959-9-19</td></tr>
<tr><td width="200">HCT</td><td width="200">41</td><td width="200">1959-7-13</td></tr>
<tr><td width="200">HGB</td><td width="200">14</td><td width="200">1959-7-13</td></tr>
<tr><td width="200">Sodium</td><td width="200">143</td><td width="200">1959-9-19</td></tr>
<tr><td width="200">Albumen</td><td width="200">4</td><td width="200">1959-9-19</td></tr>
<tr><td width="200">Creatinine</td><td width="200">1.3</td><td width="200">1959-9-19</td></tr>
<tr><td width="200">Glycosylated_Hemoglobin</td><td width="200">6</td><td width="200">1957-12-10</td></tr>
<tr><td width="200">Pulse</td><td width="200">71</td><td width="200">1959-7-28</td></tr>
<tr><td width="200">PLT</td><td width="200">168</td><td width="200">1959-7-13</td></tr>
<tr><td width="200">WBC</td><td width="200">7</td><td width="200">1959-7-13</td></tr>
<tr><td width="200">eGFR</td><td width="200">60</td><td width="200">1956-7-31</td></tr>
<tr><td width="200">SGPT</td><td width="200">39</td><td width="200">1959-9-19</td></tr>
<tr><td width="200">Sex</td><td width="200">Male</td><td width="200"></td></tr>
<tr><td width="200">Race</td><td width="200">White_Non-Hispanic</td><td width="200"></td></tr>
<tr><td width="200">Coronary_Artery_Disease</td><td width="200"></td><td width="200">1959-6-30</td></tr>
<tr><td width="200">Disorders Lipid Metabolism</td><td width="200"></td><td width="200">1959-5-31</td></tr>
<tr><td width="200">Hyperlipidemia</td><td width="200"></td><td width="200">1959-5-31</td></tr>
<tr><td width="200">Hypertension</td><td width="200"></td><td width="200">1959-7-13</td></tr>
<tr><td width="200">Myocardial_Infarction</td><td width="200"></td><td width="200">1959-5-22</td></tr>
</table>
<p><b>Medications:</b> aspirin(81.0) labetalol(5.0) simvastatin(80.0) atorvastatin(40.0) hydrochlorothiazide(12.5) 
<p><b>Problems:</b> <table>
<tr><td width="200"><b>Problem Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr><td width="200">Target_Organ_Damage_Clinical_Cardiovascular_Disease</td>
<td width="200"></td>
<td width="200"> TOD/CCD[presence of myocardial infarction]()</td></tr>
<tr><td width="200">MI (secondary prevention) BP controlled</td>
<td width="200"></td>
<td width="200"> Myocardial Infarction (Secondary Prevention)[Treatment_Diastolic_BP(68/null) && Treatment_Systolic_BP(116/null) && presence of myocardial infarction]()</td></tr>
<tr><td width="200">Major Cardiovascular Risk Factor</td>
<td width="200"></td>
<td width="200"> Major Cardiovascular Risk Factor[presence of diagnosis of hypertension]()</td></tr>
<tr><td width="200">Dyslipidemia Lab or ICD9</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab or ICD9[presence of lipid disorder ICD9]()</td></tr>
<tr><td width="200">Active prescription for thiazide</td>
<td width="200"></td>
<td width="200"> active prescription for thiazide[presence of thiazide diuretics]()</td></tr>
<tr><td width="200">on >= 1 med</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">taking >= 2 anti hypertensive meds</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">On 1 drug and there exists contraindicated drug or a compelling drug not given</td>
<td width="200"></td>
<td width="200"> On 1 drug and there exists contraindicated drug or a compelling drug not given[there exists a compellingly indicated drug that is not already given]()</td></tr>
<tr><td width="200">Hypertension with MI and K>=3.5</td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(3.9/1959-9-19) && presence of MI]()</td></tr>
<tr><td width="200">CCS-7.2</td>
<td width="200">1959-05-22</td>
<td width="200"> Myocardial_Infarction()</td></tr>
<tr> <td width="200"></td>
<td width="200">1959-06-30</td>
<td width="200"> Coronary_Artery_Disease()</td></tr>
<tr><td width="200">Hypertension_Inclusive</td>
<td width="200">1959-07-13</td>
<td width="200"> Hypertension()</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(3.9/1959-9-19) && presence of MI]()</td></tr>
<tr><td width="200">Metabolic&Nutritional_Diseases</td>
<td width="200">1959-05-31</td>
<td width="200"> Disorders Lipid Metabolism()</td></tr>
<tr><td width="200">Hypertension_Defined</td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(3.9/1959-9-19) && presence of MI]()</td></tr>
<tr><td width="200"> <b>Others</b></td>
<td width="200">1959-05-31</td>
<td width="200"> Hyperlipidemia()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Race()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Sex()
</table><p>
</patient>
<h1 align="center">VA/JNC-VII Hypertension Guideline</h1>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(presence of diagnosis of hypertension && absence of renovascular disease && no diagnosis of pregnancy && Absense of Secondary Hypertension && absence of spinal cord injury && absence of narcolepsy && Not taking cyclosporine && Not taking spironolactone && Not taking minoxidil && absence of renovascular disease && absence of IHSS && Absence of Ascites && Not off guideline && not taking tacrolimus && absence of transplant recipient && Absence of a dialysis procedure code)</i>]
<li>Risk Group C (presence of TOD/CCD or DM): [because <i> presence of TOD/CCD or DM </i> evaluate to <b>true</b><i>(presence of TOD/CCD)</i>]
</ul>
<b>Scenario choice:</b> on two or three anti-hypertensive drugs
<p>
<b>Goal:</b> SBP < 140 and DBP < 90(absence of diabetes mellitus)
<p><b>Reached goal?</b> achieved(Treatment_Diastolic_BP(68/null) && Treatment_Systolic_BP(116/null))
<p><b>Messages by Types</b>
<ul>
<li><b>Recommendation</b>
<ul>
<li>Beta blockers may have transient adverse effects on lipids in some patients.  Consider repeating lipid profile after maximal dosage of drug has been reached if appropriate.
<li>It is true that 7.3 inches of rain fell yesterday, and the patient is taking the following drugs: labetalol, hydrochlorothiazide
<li>The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.
</ul>
<li><b>Primary_Recommendation</b>
<ul>
<li>Maintain current drug choices and  continue to encourage patient adherence to his/her current regimen.
<li>Based on most recent BP in the database, BP appears to be adequately controlled; however, ALTERNATIVE DRUGS may be preferred
</ul>
<li><b>Assumption</b>
<ul>
<li>We did not find a BP in the vitals signs section of the computer.  We are not at present able to use the BP recorded in the text of the progress note, so we are not able to determine whether the BP control is adequate or inadequate.  Please enter BP using the top part of the screen.
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>on medication: things to check</b><br>
<ul>
<li><b>assumption  check presence of BP <font color=FF0000>preferred</font></b>(rule in criterion<i> diastolic BP or systolic BP absent</i> evaluate to <b> true</b> because <i>absence of diastolic BP</i>)])
We did not find a BP in the vitals signs section of the computer.  We are not at present able to use the BP recorded in the text of the progress note, so we are not able to determine whether the BP control is adequate or inadequate.  Please enter BP using the top part of the screen.
<li><b>risk group C message(on med), absence of DM <font color=FF0000>preferred</font></b>(rule in criterion<i> risk group C</i> evaluate to <b> true</b> because <i>risk group C</i>)])
This patient has clinically manifest cardiovascular disease or target organ damage (Risk Group C per JNC6).  The largest benefit of anti-hypertensive therapy is seen in patients with the highest baseline risk of cardiovascular disease, therefore this patient should be considered for prompt pharmacologic therapy, even if the BP is in the high-normal range.  Appropriate lifestyle modification and attention to other reversible cardiovascular risk factors is also strongly recommended.
<li><b>adverse event warning <font color=FF0000>preferred</font></b>(rule in criterion<i> presence of current medication with adverse reaction</i> evaluate to <b> true</b> because <i>presence of current medication with adverse reaction</i>)])
<li><b>On beta blocker hyperlipidemia <font color=FF0000>preferred</font></b>(rule in criterion<i> beta blocker being used</i> evaluate to <b> true</b> because <i>beta blocker being used</i>)])
Beta blockers may have transient adverse effects on lipids in some patients.  Consider repeating lipid profile after maximal dosage of drug has been reached if appropriate.
<li><b>test parameterized message <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
It is true that 7.3 inches of rain fell yesterday, and the patient is taking the following drugs: labetalol, hydrochlorothiazide
<li><b>Disclaimer <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.
</ul>
<li><b>two or three drug-therapy choices</b><br>
<ul>
<li><b>continue with two or three drug regimen <font color=FF0000>preferred</font></b>(strict rule-in condition<i> (~B & A &~E) cannot do better</i> evaluate to <b> true</b> because <i>(~B)no current drug contraindicatedthere exists a contraindicated current med && Treatment_Diastolic_BP(68/null) && Treatment_Systolic_BP(116/null) && (~E)no (compellingly indicated not given and current drug not indicated)there exists a non-betablocker, non-ACE, non-clonidine , non (alpha blocker + BPH)drug to replace</i>)])
Maintain current drug choices and  continue to encourage patient adherence to his/her current regimen.
<li><b>substitute labetalol w BB <font color=FF0000>preferred</font></b>(strict rule-in condition<i> presence of labetatalol, MI, absence of BPH</i> evaluate to <b> true</b> because <i>absence of BPH && presence of MI && Taking labetalol</i>)])

Based on most recent BP in the database, BP appears to be adequately controlled; however, ALTERNATIVE DRUGS may be preferred
</ul>
<li><b>substitution messages</b><br>
<ul>
<li><b>NO ADE recommended drug SUB <font color=FF0000>preferred</font></b>(rule in criterion<i> there exists recommended drug and none has ADE</i> evaluate to <b> true</b> because <i>No recommended drug has adverse event && recommend delete</i>)])
No adverse reactions are listed for the antihypertensive drug(s) we are recommending.  If the patient has had an adverse reaction, please enter it in a progress note entitled "Adverse Reactions/Allergy".
</ul>
</ul>
<b>Considerations for substituting drug: </b><ul><li> Substitution: replace <ul><li>labetalol(Alpha_beta_blockers)<ul><li>Drugs with bad interactions: <li>Relative contraindications: </ul> with <li>Cardioselective Beta Blocker (metoprolol)<ul><li>Drugs to partner:  Thiazide_Diuretics(hydrochlorothiazide) <li>Drugs with bad interactions:  Alpha_beta_blockers(labetalol) <li><font color=FF0000>Compelling indications:  Myocardial_Infarction(Myocardial_Infarction)  MI (secondary prevention) BP controlled(Myocardial Infarction (Secondary Prevention)[Treatment_Diastolic_BP(68/null) && Treatment_Systolic_BP(116/null) && presence of myocardial infarction]) </font><li>Relative indications:  Coronary_Artery_Disease(Coronary_Artery_Disease) <li>add metoprolol, adjust dose other drugs(When adding metoprolol to this patient's therapeutic regime a dose adjustment of other anti-hypertensive drugs may be required.)<li>betablocker dyslipidemia warning message(Beta blockers may have transient adverse effects on lipids in some patients.  Consider repeating lipid profile after maximal dosage of drug has been reached if appropriate.)<li>disclaimer about procedure reports delete(Diagnoses from EKG reports are not extracted. If patient has an arrythmia that is not shown in patient summary, please update problem list.)<li>MI (BB)  and JNC7 rec aldosterone antag(Beta Adrenergic Receptor Antagonist is compellingly indicated for post MI by JNC7 and 2004 VA Guidelines, JNC7 also has aldosterone antagonists as a compelling indication for MI.)<li>preference: preferred</ul></ul></ul></body></html>